Form 4: Inmune Bio Director Scott Juda Acquires Options in Company Stock

Director Scott Juda acquired options to purchase 12,500 shares of Inmune Bio stock at $9.92 per share, vesting monthly over one year.

Summary

• On May 14, 2024, Scott Juda, a director of Inmune Bio, Inc., was granted options to purchase 12,500 shares of the company's common stock.
• The exercise price for these options is $9.92 per share.
• The options were granted pursuant to the 2021 Stock Incentive Plan.
• The options vest in equal monthly installments over one year, becoming fully vested on the one-year anniversary of the grant date.
• The options expire on May 13, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, designed to incentivize continued service and alignment with long-term company performance.
• Comparable companies often use similar stock incentive plans to attract and retain talent.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to incentivizing its leadership.

Key Dates